Potassium Chloride In Dextrose And Sodium Chloride

Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride


Fresenius Kabi Usa, Llc
Human Prescription Drug
NDC 65219-142
Potassium Chloride In Dextrose And Sodium Chloride also known as Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride is a human prescription drug labeled by 'Fresenius Kabi Usa, Llc'. National Drug Code (NDC) number for Potassium Chloride In Dextrose And Sodium Chloride is 65219-142. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Potassium Chloride In Dextrose And Sodium Chloride drug includes Dextrose Monohydrate - 50 g/1000mL Potassium Chloride - .745 g/1000mL Sodium Chloride - 4.5 g/1000mL . The currest status of Potassium Chloride In Dextrose And Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 65219-142
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Potassium Chloride In Dextrose And Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Fresenius Kabi Usa, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DEXTROSE MONOHYDRATE - 50 g/1000mL
POTASSIUM CHLORIDE - .745 g/1000mL
SODIUM CHLORIDE - 4.5 g/1000mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 26 Aug, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA213523
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Fresenius Kabi USA, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:615099
615100
630796
1863605
1863607
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:LX22YL083G
660YQ98I10
451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Potassium Compounds [CS]
Potassium Salt [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
65219-142-1010 BAG in 1 CASE (65219-142-10) / 1000 mL in 1 BAG (65219-142-02)26 Aug, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.
Other medicines with the same generic name

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7902

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7903

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7993

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
Fresenius Kabi USA, LLC
NDC: 65219-146

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
Fresenius Kabi USA, LLC
NDC: 65219-151

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7107

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
Fresenius Kabi USA, LLC
NDC: 65219-118

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
Fresenius Kabi USA, LLC
NDC: 65219-142

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7904

Potassium Chloride In Dextrose And Sodium Chloride


Dextrose Monohydrate, Sodium Chloride, And Potassium Chloride

Injection, Solution
ICU Medical Inc.
NDC: 0990-7901

Product Elements:

Potassium chloride in dextrose and sodium chloride dextrose monohydrate, sodium chloride, and potassium chloride dextrose monohydrate anhydrous dextrose sodium chloride sodium cation chloride ion potassium chloride potassium cation chloride ion water hydrochloric acid potassium chloride in dextrose and sodium chloride dextrose monohydrate, sodium chloride, and potassium chloride dextrose monohydrate anhydrous dextrose sodium chloride sodium cation chloride ion potassium chloride potassium cation chloride ion water hydrochloric acid potassium chloride in dextrose and sodium chloride dextrose monohydrate, sodium chloride, and potassium chloride dextrose monohydrate anhydrous dextrose sodium chloride sodium cation chloride ion potassium chloride potassium cation chloride ion water hydrochloric acid potassium chloride in dextrose and sodium chloride dextrose monohydrate, sodium chloride, and potassium chloride dextrose monohydrate anhydrous dextrose sodium chloride sodium cation chloride ion potassium chloride potassium cation chloride ion water hydrochloric acid potassium chloride in dextrose and sodium chloride dextrose monohydrate, sodium chloride, and potassium chloride dextrose monohydrate anhydrous dextrose sodium chloride sodium cation chloride ion potassium chloride potassium cation chloride ion water hydrochloric acid

Drug Interactions:

Drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. see precautions .

Indications and Usage:

Indications and usage these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride.

Warnings:

Warnings solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. to avoid potassium intoxication, do not infuse these solutions rapidly. in patients with severe renal insufficiency or adrenal insufficiency, administration of potassium chloride may cause potassium intoxication. solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. in patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. the intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk
of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. the risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

Dosage and Administration:

Dosage and administration these solutions should be administered only by intravenous infusion and as directed by the physician. the dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. if the serum potassium level is greater than 2.5 meq/liter, potassium should be given at a rate not to exceed 10 meq/hour in a concentration less than 30 meq/liter. somewhat faster rates and greater concentrations (usually up to 40 meq/liter) of potassium may be indicated in patients with more severe potassium deficiency. the total 24- hour dose should not generally exceed 200 meq of potassium. as reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing addit
ives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. see precautions .

Contraindications:

Contraindications solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered.

Adverse Reactions:

Adverse reactions reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. the signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of p waves, spreading and slurring of the qrs complex with development of a biphasic curve and cardiac arrest. potassium-containing solutions are intrinsically i
rritating to tissues. therefore, extreme care should be taken to avoid perivascular infiltration. local tissue necrosis and subsequent sloughing may result if extravasation occurs. chemical phlebitis and venospasm have also been reported. should perivascular infiltration occur, i.v. administration at that site should be discontinued at once. local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, will often reduce venospasm and dilute the potassium remaining in the tissues locally. local application of heat may also be helpful. to report suspected adverse reactions, contact fresenius kabi usa, llc at 1-800-551-7176 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug Interactions:

Drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. see precautions .

Use in Pregnancy:

Pregnancy animal reproduction studies have not been conducted with dextrose, potassium chloride or sodium chloride. it is also not known whether dextrose, potassium chloride or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. dextrose, potassium chloride or sodium chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use: the safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. in neonates or very small infants the volume of fluid may affect fluid and electrolyte balance. frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. in very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

Geriatric Use:

Geriatric use: an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. sodium and potassium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage in the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels. see warnings and precautions .

Description:

Description intravenous solutions with potassium chloride (i.v. solutions with kcl) are sterile and nonpyrogenic solutions in water for injection. they are for administration by intravenous infusion only. see table below for summary of content and characteristics of these solutions. table 1 composition (g/l) approx. ionic concentrations (meq/l) potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp meq potassium size (ml) dextrose, hydrous sodium chloride potassium chloride calculated osmolarity (mosmol/l) ph sodium (na + ) potassium (k + ) chloride (cl - ) approximate kcal/l 10 meq 500 50 4.5 1.49 447 4.2 (3.5 to 6.5) 77 20 97 170 10 meq 1000 50 4.5 0.745 426 4.2 (3.5 to 6.5) 77 10 87 170 20 meq 1000 50 4.5 1.49 447 4.2 (3.5 to 6.5) 77 20 97 170 30 meq 1000 50 4.5 2.24 467 4.2 (3.5 to 6.5) 77 30 107 170 40 meq 1000 50 4.5 2.98 487 4.2 (3.5 to 6.5) 77 40 117 170 may contain hcl for ph adjustment. the solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only for use as a single-dose injection. when smaller doses are required the unused portion should be discarded. these solutions are parenteral fluid, nutrient and/or electrolyte replenishers. dextrose, usp is chemically designated d-glucose, monohydrate (c 6 h 12 o 6 • h 2 o), a hexose sugar freely soluble in water. it has the following structural formula: potassium chloride, usp is chemically designated kcl, a white granular powder freely soluble in water. sodium chloride, usp is chemically designated nacl, a white crystalline powder freely soluble in water. water for injection, usp is chemically designated h 2 o. the flexible plastic container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers ( free flex ® bag) . water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. exposure to temperatures above 25°c/77°f during transport and storage will lead to minor losses in the moisture content. higher temperatures lead to greater losses. it is unlikely that these minor losses will lead to clinically significant changes within the expiration period. figure

Clinical Pharmacology:

Clinical pharmacology when administered intravenously, these solutions provide a source of water and potassium chloride with carbohydrate (dextrose) and sodium chloride. see how supplied section for specific concentrations of these various solutions. solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein- sparing action. dextrose injected parenterally undergoes oxidation to carbon dioxide and water. intravenous solutions containing potassium chloride are particularly intended to provide needed potassium cation (k + ). potassium is the chief cation of body cells (160 meq/liter of intracellular water). it is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 meq/liter in a healthy adult). potassium plays an important role in electrolyte balance. normally about 80 to 90% of the potassium intake is excreted in
the urine; the remainder in the stools and to a small extent, in the perspiration. the kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. a deficiency of either potassium or chloride will lead to a deficit of the other. sodium chloride in water dissociates to provide sodium (na + ) and chloride (cl − ) ions. sodium (na + ) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. chloride (cl − ) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. the distribution and excretion of sodium (na + ) and chloride (cl − ) are largely under the control of the kidney which maintains a balance between intake and output. water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). water balance is maintained by various regulatory mechanisms. water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (na + ) plays a major role in maintaining physiologic equilibrium.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility: studies with solutions from flexible plastic containers have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

How Supplied:

How supplied potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp is supplied in single-dose free flex ® plastic containers as follows: product code unit of use strength unit of sale 245075 ndc 65219-150-00 one 500 ml free flex ® bag 10 meq potassium chloride ndc 65219-150-75 package of 20 free flex ® bags 224210 ndc 65219-142-02 one 1000 ml free flex ® bag 10 meq potassium chloride ndc 65219-142-10 package of 10 free flex ® bags 244410 ndc 65219-144-04 one 1000 ml free flex ® bag 20 meq potassium chloride ndc 65219-144-10 package of 10 free flex ® bags 244610 ndc 65219-146-06 one 1000 ml free flex ® bag 30 meq potassium chloride ndc 65219-146-10 package of 10 free flex ® bags 244810 ndc 65219-148-08 one 1000 ml free flex ® bag 40 meq potassium chloride ndc 65219-148-10 package of 10 free flex ® bags avoid excessive heat. store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. the conta
iner closure is not made with natural rubber latex. non-pvc, non-dehp, sterile.

Package Label Principal Display Panel:

Package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label 10 meq potassium 1000 ml ndc 65219- 142 -02 free flex ® 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp rx only package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label

Package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label ndc 65219-142-10 224210 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml x 10 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. avoid excessive heat. package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label

Package label - principal display – 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label 20 meq potassium 1000 ml ndc 65219- 144 -04 free flex ® 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp rx only package label - principal display – 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label

Package label - principal display – 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label ndc 65219-144-10 244410 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml x 10 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. avoid excessive heat. package label - principal display – 20 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label

Package label - principal display – 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label 30 meq potassium 1000 ml ndc 65219- 146 -06 free flex ® 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp rx only package label - principal display – 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label

Package label - principal display – 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label ndc 65219-146-10 244610 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml x 10 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. avoid excessive heat. package label - principal display – 30 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label

Package label - principal display – 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label 40 meq potassium 1000 ml ndc 65219- 148 -08 free flex ® 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp rx only package label - principal display – 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml bag label

Package label - principal display – 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label ndc 65219-148-10 244810 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 1000 ml x 10 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. avoid excessive heat. package label - principal display – 40 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label

Package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 500 ml bag label 10 meq potassium 500 ml ndc 65219- 150 -00 free flex ® 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp rx only package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 500 ml bag label

Package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label ndc 65219-150-75 245075 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp 500 ml x 20 store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from freezing. avoid excessive heat. package label - principal display – 10 meq potassium chloride in 5% dextrose and 0.45% sodium chloride injection, usp case label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.